title: [The assessment of Helicobacter pylori eradication with the urea breathing test (13C UBT)].
abstract: The purpose of the study was to assess the efficacy of Helicobacter pylori (HP) infection treatment in children with the nephrotic syndrome, using non-invasive urea breathing test (13C UBT). The study comprised 20 children with nephrotic syndrome treated with prednisone. Children were divided into two groups: those who recurred prednisone for a short time (1-3 months) and those treated longer than 6 months. In all children gastroscopic examination, histopathologic assessment of gastric mucous membrane specimens and 13C UBT were performed. 65% of nephrotic children was HP (+). In those treated for 1-3 months incidence of HP infection was 40%, whereas in those were treated longer than 6 months it was 90%. In all children treatment of HP infection was instituted. Seven weeks after cessation of treatment its efficacy was assessed by 13C UBT. The treatment was successful in all nephrotic children. In the nephrotic controls with negative histopathologic assessment for HP infection the results of UBT were normal.
  
  
  CONCLUSIONS
  1. Children with the nephrotic syndrome are more susceptible to HP infection as compared with healthy ones. 2. In those children treatment of HP infection is efficient. 3. 13C UBT allows to estimate HP infection treatment efficacy in a non-invasive way.
authors.affiliation: Kliniki Pediatrii i Nefrologii AM w Lublinie.
authors.forename: M
authors.initials: M
authors.lastname: Zajaczkowska
authors.forename: T
authors.initials: T
authors.lastname: Durakiewicz
authors.forename: A
authors.initials: A
authors.lastname: Papierkowski
mesh_terms: D000293:Adolescent; D000893:Anti-Inflammatory Agents / Q000627:therapeutic use*; D001944:Breath Tests; D002648:Child; D002675:Child, Preschool; D005260:Female; D016481:Helicobacter Infections / Q000150:complications / Q000188:drug therapy* / Q000453:epidemiology; D016480:Helicobacter pylori; D006801:Humans; D008297:Male; D009404:Nephrotic Syndrome / Q000150:complications / Q000188:drug therapy; D011241:Prednisone / Q000627:therapeutic use*; D016896:Treatment Outcome; D014508:Urea / Q000032:analysis*
chemical_list: D000893:Anti-Inflammatory Agents; D014508:Urea; D011241:Prednisone